Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PFE stock, giving a Hold rating on April 11.
Terence Flynn has given his Hold rating due to a combination of factors surrounding Pfizer’s recent decision to discontinue the development of its oral GLP-1 drug, Danuglipron. Despite meeting key pharmacokinetic objectives in dose-optimization studies, the program was halted following a potential drug-induced liver injury in a participant, although this was an isolated incident and resolved after discontinuation.
Flynn anticipates a limited impact on Pfizer’s stock, as investor expectations for Danuglipron were already low, and the shares are supported by a dividend yield exceeding 7%. Furthermore, the projected sales for Danuglipron in 2033 are a small fraction of Pfizer’s total sales, suggesting that the discontinuation will not significantly affect the company’s financial outlook.
According to TipRanks, Flynn is a 3-star analyst with an average return of 1.9% and a 50.00% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Gilead Sciences, and Merck & Company.
In another report released on April 11, Citi also maintained a Hold rating on the stock with a $23.00 price target.